Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26312165 | 1.00 | KMT2A (0.38) | KMT2AFABP5FABP7CASP3MMP2 | |
| SCHEMBL26314523 | 1.00 | KMT2A (0.38) | KMT2AFABP5FABP7CASP3MMP2 | |
| SCHEMBL29400870 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL | |
| SCHEMBL3728170 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL | |
| SCHEMBL29908641 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL | |
| SCHEMBL31732619 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL | |
| SCHEMBL119027 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL | |
| SCHEMBL29401170 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL | |
| SCHEMBL30896130 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL | |
| SCHEMBL1486163 | 0.90 | FABP5 (0.43) | KMT2AFABP5FABP7CASP3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4144747-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-08 | — | — | EP | disclosed |
| CN-115698032-A | Efficient peptide condensation of difficult sequences | 中外制药株式会社 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | KMT2A 3727/4885FABP5 2084/4885FABP7 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.